%0 Journal Article %A Elisa E Cornish %A Kelvin YC Teo %A Mark C Gillies %A Lyndell L Lim %A Vuong Nguyen %A Sanjeewa Wickremasinghe %A Hemal Mehta %A Ian L McAllister %A Samantha Fraser-Bell %T Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamethasone implants for diabetic macular oedema %D 2023 %R 10.1136/bjophthalmol-2021-319839 %J British Journal of Ophthalmology %P 79-83 %V 107 %N 1 %X Background The BEVORDEX trial compared outcomes of eyes with diabetic macular oedema (DMO) randomised to receive either intravitreal dexamethasone (DEX-) implant or bevacizumab over 2 years. We assessed long-term efficacy and safety outcomes 5 years from enrolment.Methods Patients received standard clinical care after they finished the study. Their files were reviewed for visual and anatomical outcomes, post-trial treatments and complications.Results Three-year and five-year data were available for 82% and 59% of eyes enrolled in the BEVORDEX study, respectively. Visual acuity gains at end of trial were generally lost by both treatment groups at 5 years but the macular thickness did not change from end of trial to 5 years. A similar proportion of eyes from each treatment group gained ≥10 letters at 5 years from enrolment in the BEVORDEX trial.Eyes that were initially randomised to the DEX-implant group had significantly fewer treatments but were more likely to develop proliferative diabetic retinopathy (PDR) over the 5-year period compared with eyes initially randomised to bevacizumab. The proportion of eyes that had cataract surgery by 5 years was similar between initial treatment groups.Conclusions Eyes in the BEVORDEX trial had similar 5-year rates of cataract surgery, however, more eyes converted to PDR in the group initially treated with DEX-implant. Eyes that were initially treated for 2 years with either intravitreal DEX-implant of bevacizumab followed by standard of care had similar visual and anatomical outcomes at 5 years.Data are available upon reasonable request. Data are available upon reasonable request to the corresponding author. %U https://bjo.bmj.com/content/bjophthalmol/107/1/79.full.pdf